Related Experiment Video

Updated: Jul 25, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

208

CCR2 antagonist represses fibroblast-like synoviocyte-mediated inflammation in patients with rheumatoid arthritis

Ruilin Li1, Xuming Wu2, Song Peng3

  • 1Department of Pharmacy, The Third Affiliated Hospital of Anhui Medical University, Hefei, China; Hefei First People's Hospital, Hefei, China.

International Immunopharmacology
|June 30, 2023
PubMed

Insights

A novel C-C chemokine receptor type 2 (CCR2) antagonist shows promise for treating rheumatoid arthritis (RA). This drug targets RA Fibroblast-like synoviocytes, reducing inflammation and improving joint health in preclinical models.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a prevalent autoimmune disease with complex pathogenesis.
  • Current RA treatments have limitations, including side effects and drug resistance.
  • C-C chemokine receptor type 2 (CCR2) is a potential therapeutic target for RA.

Purpose of the Study:

  • To investigate the role of CCR2 in RA pathogenesis.
  • To evaluate the therapeutic potential of CCR2 antagonists in RA.
  • To elucidate the mechanism of action of CCR2 antagonists on RA Fibroblast-like synoviocytes (RA-FLS).

Main Methods:

  • Analysis of CCR2 expression in primary RA-FLS.
  • Assessment of CCR2 antagonist effects on RA-FLS cytokine and matrix metalloproteinase release.
  • Evaluation of CCR2 antagonist impact on RA-FLS proliferation and migration.
  • Investigation of CCR2 antagonist effects on macrophage-mediated inflammation and chondrocyte viability.
  • Assessment of CCR2 antagonist efficacy in a collagen-induced arthritis (CIA) mouse model.
  • Exploration of the JAK-STAT pathway in CCR2 antagonist-mediated anti-inflammatory effects.

Main Results:

  • CCR2 is expressed in primary RA-FLS.
  • CCR2 antagonists inhibited inflammatory cytokines and matrix metalloproteinases from RA-FLS without affecting proliferation or migration.
  • CCR2 antagonist-treated RA-FLS reduced macrophage-mediated inflammation and enhanced chondrocyte viability.
  • A CCR2 antagonist ameliorated collagen-induced arthritis in a mouse model.
  • CCR2 antagonists may exert anti-inflammatory effects via the JAK-STAT pathway.

Conclusions:

  • CCR2 antagonists demonstrate anti-inflammatory effects by acting on RA-FLS.
  • Targeting CCR2 on RA-FLS offers a promising therapeutic strategy for rheumatoid arthritis.
  • This study provides a new experimental basis for developing CCR2 antagonist-based RA drugs.
Keywords:
CCR2CytokinesMMPsRA-FLSRheumatoid arthritis

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

264
Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients09:31

Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients

Published on: October 16, 2016

9.5K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
200
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
156
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.0K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
155